Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial. J of Skin [Internet]. 2022 Nov. 16 [cited 2025 Apr. 19];6(6):s70. Available from: https://skin.dermsquared.com/skin/article/view/1826